This contract expires in 22 days (Jun 28, 2026).
MASSACHUSETTS INSTITUTE OF TECHNOLOGY - THIS REQUIREMENT IS FOR THE GENERATION OF A BAA TO ADDRESS THE ONGOING GROWTH IN CONTINUOUS MANUFACTURING WITHIN CELL LINES. THIS REQUIREMENT IS BEING FUNDED THROUGH THE PRESIDENT'S TARGET INCREASE FOR FOCUS ON ADVANCE MANUFACTURING AND WILL FOC
Key Details
Description
THIS REQUIREMENT IS FOR THE GENERATION OF A BAA TO ADDRESS THE ONGOING GROWTH IN CONTINUOUS MANUFACTURING WITHIN CELL LINES. THIS REQUIREMENT IS BEING FUNDED THROUGH THE PRESIDENT'S TARGET INCREASE FOR FOCUS ON ADVANCE MANUFACTURING AND WILL FOC
Context & Analysis
On Dec 22, 2025, Department of Health and Human Services obligated $1,832,572 to MASSACHUSETTS INSTITUTE OF TECHNOLOGY for this requirement is for the generation of a baa to address the ongoing growth in continuous manufacturing within cell lines. this requirement is being funded through the president's target increase fo…. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: competed under sap with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in CAMBRIDGE, MA. The contract is scheduled through Jun 28, 2026 — approximately 1 month remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.